

## **EQA FOR MOLECULAR INFECTIOUS DISEASE TESTING**

# EQA FOR MOLECULAR INFECTIOUS DISEASE TESTING

QCMD (Quality Control for Molecular Diagnostics) is an independent External Quality Assessment (EQA) / Proficiency Testing (PT) scheme specialising in molecular testing of a wide range of infectious diseases.

<b>IMPORTANCE OF EQA</b>	<b>01</b>
<b>BENEFITS</b>	<b>02</b>
<b>HOW IT WORKS</b>	<b>03</b>
<b>BACTERIAL EQA PROGRAMMES</b>	<b>04</b>
<b>FUNGAL EQA PROGRAMMES</b>	<b>16</b>
<b>MULTI-PATHOGEN / SYNDROMIC PROGRAMMES</b>	<b>19</b>
<b>VIRAL EQA PROGRAMMES</b>	<b>26</b>
<b>PILOT STUDIES</b>	<b>51</b>
<b>INDEX</b>	<b>56</b>
<b>APPENDIX</b>	<b>60</b>

# IMPORTANCE OF EXTERNAL QUALITY ASSESSMENT

**External Quality Assessment (EQA) or Proficiency Testing (PT) provides a means of periodically assessing a laboratory's performance in comparison with other laboratories using the same method and instrument.**

**Unlike Internal Quality Control (IQC), EQA provides an effective method of monitoring a laboratory's bias or accuracy through the analysis of 'blind samples'. Participation in an EQA scheme like QCMD will also support regulatory requirements and will assist in quality improvements.**

EQA plays an essential role in assuring laboratory quality by supporting daily IQC. It facilitates interlaboratory performance comparison and encourages greater standardisation in testing. EQA has a number of functions:

- **Helps maintain and improve the analytical quality of laboratory tests**
- **Provides an objective view of test system performance that IQC alone cannot provide**
- **Helps improve interlaboratory agreement**
- **Initiates corrective and preventative actions to resolve problems**

Furthermore, participating in an EQA scheme is often a prerequisite to gaining accreditation, ISO 15189 states, "the laboratory shall participate in interlaboratory comparisons such as those organised by external quality assessment schemes".

In short, participation in an EQA scheme will give labs greater confidence and will provide evidence that the patient results they are reporting are reliable and accurate.

## BENEFITS



### EXTENSIVE PROGRAMME OFFERING

Boasting the largest selection of molecular EQA programmes for infectious disease testing, you are sure to find what you're looking for.



### FREQUENCY

Choose between one, two and four challenges\* per year to suit your laboratory requirements. Reports are available within 2 weeks of the submission deadline (up to 4 weeks for the drug resistance / sequence based schemes), ensuring any corrective actions can be taken quickly.



### HIGH QUALITY MATERIAL

The availability of whole pathogen samples in clinically relevant matrices mimics the performance of patient samples and ensures samples can be used to effectively monitor the performance of the entire testing process.



### INTERNATIONAL ACCREDITATION

Where appropriate the EQA schemes are accredited to ISO 17043:2010 highlighting the superior quality and organisation of the QCMD scheme.



### ONLINE EQA MANAGEMENT SYSTEM

IT EQA Management System (ITEMS) provides an online tool to easily manage all EQA activities from programme registration to submission of results and provision of EQA reports.



### HIGH LEVEL OF PARTICIPATION

With over 10,000 participant registrations in more than 100 countries, peer groups are maximised, increasing statistical validity.



### COMPREHENSIVE REPORTS


Individual reports are provided with each EQA challenge. In line with the requirements of ISO17043, they provide the laboratories with their results and performance assessment in relation to their EQA assessment group (peer review group).

Supplementary reports which include scientific expert commentary may be provided at the end of the EQA cycle if appropriate.

## HOW IT WORKS

The QCMD portfolio is extensive covering over 300 target organisms across more than 90 EQA programmes and pilot studies.

The following diagram provides an overview of the schemes operation.



# BACTERIAL EQA PROGRAMMES

## ATYPICAL MYCOBACTERIUM

NTM21

Designed to evaluate the ability to detect and differentiate Atypical mycobacterium or non-tuberculous mycobacterium using routine molecular methods.

	Available Format(s)
Catalogue Number	QAB194208_1
Total Number of Challenges	1
Number of Samples	10
Distribution / Testing Period	Q2

### Specifications

**Target Pathogen** – Atypical mycobacterium or non-tuberculous mycobacterium (NTM)

**NA Target Source** – Cultured and/or Clinical material

**Matrix** – Transport Medium and/or Physiological Buffer

**Sample Volume** – 1 ml

**Analysis Type** – Qualitative

**Format** – Liquid ready-to-use

**Accreditation** – ISO17043

---

## BACTERIAL 16S RIBOSOMAL RNA

B16SrRNA21

Designed to evaluate the ability to detect, identify and interpret which bacterial species are provided within each panel member using routine 16S rRNA molecular diagnostic procedures.

	Available Format(s)
Catalogue Number	QAB164183_1
Total Number of Challenges	1
Number of Samples	8
Distribution / Testing Period	Q4

### Specifications

**Target Pathogen** – May include clinically relevant species of *Serratia*, *Escherichia*, *Staphylococcus*, *Enterococcus* and *Klebsiella*.

**Matrix** – Physiological Buffer

**Sample Volume** – 0.5 ml

**Analysis Type** – Molecular typing

**Format** – Liquid frozen

**Accreditation** – ISO17043

## BORDETELLA PERTUSSIS

BPDNA21

Designed to evaluate the ability to detect *Bordetella pertussis* using molecular methods.

	Available Format(s)
Catalogue Number	QAB094132_1
Total Number of Challenges	1
Number of Samples	10
Distribution / Testing Period	Q2

### Specifications

**Target Pathogen** – *Bordetella pertussis*

**Matrix** – Physiological Buffer

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## BORRELIA BURGDORFERI SPP. (LYME DISEASE)

BbDNA21

Designed to assess the qualitative detection of *Borrelia burgdorferi* sensu lato genospecies complex at different concentrations.

	Available Format(s)
Catalogue Number	QAB114147_1
Total Number of Challenges	1
Number of Samples	10
Distribution / Testing Period	Q3

### Specifications

**Target Pathogen** – *Borrelia burgdorferi* spp.

**Matrix** – Microbiological Medium and/or Transport Medium

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

## CHLAMYDIA PSITTACI

CPS21

Designed to evaluate the ability to detect *Chlamydia psittaci* using molecular methods.

	Available Format(s)
Catalogue Number	QAB134165_1
Total Number of Challenges	1
Number of Samples	8
Distribution / Testing Period	Q2

### Specifications

**Target Pathogen** – *Chlamydia psittaci*

**Matrix** – Transport Medium

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## CHLAMYDIA TRACHOMATIS

CTDNA21

Designed to assess the qualitative detection of *Chlamydia trachomatis* at various concentrations, and the ability to correctly identify different *C. trachomatis* strains using molecular methods.

	Available Format(s)	
Catalogue Number	QAB004101_1	QAB004101_2
Total Number of Challenges	1	2
Number of Samples	10	5
Distribution / Testing Period	Q3	Q1 and Q3

### Specifications

**Target Pathogen** – *Chlamydia trachomatis*

**Matrix** – Urine and/or Physiological Buffer

**Sample Volume** – 4.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043



## CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE

CTNg21

Designed to evaluate the ability to detect *Chlamydia trachomatis* and *Neisseria gonorrhoeae* using molecular methods.

	Available Format(s)	
Catalogue Number	QAB174191_1	QAB174191_2
Total Number of Challenges	1	2
Number of Samples	10	5
Distribution / Testing Period	Q3	Q1 and Q3

### Specifications

**Target Pathogen** – *Chlamydia trachomatis*; *Neisseria gonorrhoeae*

**Matrix** – Urine and/or Physiological Buffer

**Sample Volume** – 4.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## CHLAMYDOPHILA PNEUMONIAE

CP21

Designed to evaluate the ability to detect *Chlamydophila pneumoniae* using molecular methods.

	Available Format(s)
Catalogue Number	QAB084107_1
Total Number of Challenges	1
Number of Samples	5
Distribution / Testing Period	Q2

### Specifications

**Target Pathogen** – *Chlamydophila pneumoniae*

**Matrix** – Bronchoalveolar Lavage (BAL) and/or Transport Medium

**Sample Volume** – 0.5 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

## CLOSTRIDIUM DIFFICILE (CD)

CDDNA21

Designed to evaluate the ability to detect *Clostridium difficile* using molecular methods.

	Available Format(s)	
Catalogue Number	QAB084125_1	QAB084125_2
Total Number of Challenges	1	2
Number of Samples	10	5
Distribution / Testing Period	Q4	Q2 and Q4

### Specifications

**Target Pathogen** – *Clostridium difficile* (CD)

**Matrix** – Microbiological Medium and/or Synthetic Faecal Matrix

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## DIARRHEAGENIC ESCHERICHIA COLI

E.COLI21

Designed to evaluate the ability to detect diarrheagenic *Escherichia coli* strains using routine molecular methods.

	Available Format(s)	
Catalogue Number	QAB154179_1	
Total Number of Challenges	1	
Number of Samples	8	
Distribution / Testing Period	Q4	

### Specifications

**Target Pathogen** – Diarrheagenic *Escherichia coli*

**Matrix** – Synthetic Faecal Matrix and/or Physiological Buffer

**Sample Volume** – 1.0 ml

**Analysis Type** – Molecular typing

**Format** – Liquid frozen

**Accreditation** – ISO17043

## EXTENDED SPECTRUM $\beta$ -LACTAMASE AND CARBAPENEMASE

ESBL21

Designed to evaluate the ability to detect and determine different ESBL and Carbapenemases in a clinical setting.

	Available Format(s)
Catalogue Number	QAB134162_1
Total Number of Challenges	1
Number of Samples	8
Distribution / Testing Period	Q3

### Specifications

**Target Pathogen** – Various bacteria carrying ESBL and carbapenemase genes

**Matrix** – Physiological Buffer

**Sample Volume** – 0.5 ml

**Analysis Type** – Molecular typing

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## GROUP B STREPTOCOCCUS

GBS21

Designed to assess the ability to detect Group B *Streptococcus* using routine molecular methods.

	Available Format(s)
Catalogue Number	QAB174200_1
Total Number of Challenges	1
Number of Samples	8
Distribution / Testing Period	Q4

### Specifications

**Target Pathogen** – *Streptococcus agalactiae*

**Matrix** – Plasma, Synthetic CSF and/or Transport Medium

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

## HELICOBACTER PYLORI

H.PYLORI21

Designed to assess the qualitative detection of *H. pylori* and where appropriate, the identification of *H. pylori* antibiotic resistance status using routine molecular methods.

	Available Format(s)
Catalogue Number	QAB164190_1
Total Number of Challenges	1
Number of Samples	10
Distribution / Testing Period	Q3

### Specifications

**Target Pathogen** – *Helicobacter pylori*

**Matrix** – Synthetic Faecal Matrix and/or Physiological Buffer

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative. Quantitative for information purposes only

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## LEGIONELLA PNEUMOPHILA

LPDNA21

Designed to evaluate the ability to detect *Legionella pneumophila* using molecular methods.

	Available Format(s)
Catalogue Number	QAB044122_1
Total Number of Challenges	1
Number of Samples	10
Distribution / Testing Period	Q1

### Specifications

**Target Pathogen** – *Legionella pneumophila*

**Matrix** – Bronchoalveolar lavage (BAL) and/or Transport Medium

**Sample Volume** – 0.5 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

## METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA)

MRSADNA21

Designed to evaluate the ability to detect Methicillin Resistant *Staphylococcus aureus* using molecular methods.

	Available Format(s)
Catalogue Number	QAB064124_1
Total Number of Challenges	1
Number of Samples	10
Distribution / Testing Period	Q4

### Specifications

**Target Pathogen** – Methicillin Resistant *Staphylococcus aureus* (MRSA)

**Matrix** – Microbiological Medium and/or Transport Medium

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid ready-to-use

**Accreditation** – ISO17043

---

## METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) – TYPING

*(epidemiology and outbreak studies)*

MRSATP21

Designed to evaluate the ability to use molecular typing for outbreak analysis of Methicillin Resistant *Staphylococcus aureus* (MRSA).

	Available Format(s)
Catalogue Number	QAB074128_1
Total Number of Challenges	1
Number of Samples	8
Distribution / Testing Period	Q4

### Specifications

**Target Pathogen** – Methicillin Resistant *Staphylococcus aureus* (MRSA)

**Matrix** – Microbiological Medium and/or Transport Medium

**Sample Volume** – 0.2 ml

**Analysis Type** – Molecular typing

**Format** – Liquid ready-to-use

**Accreditation** – ISO17043

## MYCOBACTERIUM TUBERCULOSIS (MTB)

### MTBDNA21

Designed to evaluate the ability to detect *Mycobacterium tuberculosis* using molecular methods.

	Available Format(s)	
Catalogue Number	QAB014129_1	QAB014129_2
Total Number of Challenges	1	2
Number of Samples	10	5
Distribution / Testing Period	Q4	Q2 and Q4

### Specifications

**Target Pathogen** – *Mycobacterium tuberculosis*

**Matrix** – Sputum and/or Synthetic Sputum and/or Synthetic CSF

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid ready-to-use

**Accreditation** – ISO17043

## MYCOBACTERIUM TUBERCULOSIS DRUG RESISTANCE

### MTBDR21

Designed to evaluate the ability to detect and differentiate *Mycobacterium tuberculosis* drug resistant strains using routine molecular methods.

	Available Format(s)	
Catalogue Number	QAB194209_1	
Total Number of Challenges	1	
Number of Samples	8	
Distribution / Testing Period	Q4	

### Specifications

**Target Pathogen** – *Mycobacterium tuberculosis*

**NA Target Source** – Cultured and/or Clinical material

**Matrix** – Sputum and/or Synthetic Sputum and/or Synthetic CSF

**Sample Volume** – 1.0 ml

**Analysis Type** – Molecular typing

**Format** – Liquid ready-to-use

**Accreditation** – ISO17043

## MYCOPLASMA GENITALIUM

MG21

Designed to evaluate the ability to detect *Mycoplasma genitalium* using routine molecular methods.

	Available Format(s)
Catalogue Number	QAB184205_1
Total Number of Challenges	1
Number of Samples	10
Distribution / Testing Period	Q3

### Specifications

**Target Pathogen** – *Mycoplasma genitalium*

**NA Target Source** – Cultured and/or Clinical material

**Matrix** – Urine and/or Saline

**Sample Volume** – 4.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## MYCOPLASMA PNEUMONIAE

MP21

Designed to evaluate the ability to detect *Mycoplasma pneumoniae* using molecular methods.

	Available Format(s)
Catalogue Number	QAB174192_1
Total Number of Challenges	1
Number of Samples	5
Distribution / Testing Period	Q2

### Specifications

**Target Pathogen** – *Mycoplasma pneumoniae*

**Matrix** – Bronchoalveolar lavage (BAL) and/or Transport Medium

**Sample Volume** – 0.5 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

## MYCOPLASMA SPP. (CELL CONTAMINATION)

MYCO21

Designed to evaluate the ability to detect and quantitate *Mycoplasma* species using molecular methods.

	Available Format(s)
Catalogue Number	QAB144168_1
Total Number of Challenges	1
Number of Samples	10
Distribution / Testing Period	Q4

### Specifications

**Target Pathogen** – *Mycoplasma* species

**Matrix** – Physiological Buffer

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative & Quantitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## NEISSERIA GONORRHOEAE

NgDNA21

Designed to evaluate the ability to detect *Neisseria gonorrhoeae* using molecular technologies.

	Available Format(s)	
Catalogue Number	QAB034126_1	QAB034126_2
Total Number of Challenges	1	2
Number of Samples	10	5
Distribution / Testing Period	Q3	Q1 and Q3

### Specifications

**Target Pathogen** – *Neisseria gonorrhoeae*

**Matrix** – Urine and/or Physiological Buffer

**Sample Volume** – 4.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043



## STAPHYLOCOCCUS AUREUS SPA

SASPA21

Designed to evaluate the ability to use molecular typing as a technique for identifying *Staphylococcus aureus*.

	Available Format(s)
Catalogue Number	QAB134164_1
Total Number of Challenges	1
Number of Samples	6
Distribution / Testing Period	Q4

### Specifications

**Target Pathogen** – *Staphylococcus aureus*

**Matrix** – Microbiological Medium and/or Transport Medium

**Sample Volume** – 0.2 ml

**Analysis Type** – Molecular typing

**Format** – Liquid ready-to-use

**Accreditation** – ISO17043

---

## SYPHILIS

SYPH21

Designed to evaluate the ability to detect *Treponema pallidum* using molecular methods.

	Available Format(s)
Catalogue Number	QAB154180_1
Total Number of Challenges	1
Number of Samples	8
Distribution / Testing Period	Q4

### Specifications

**Target Pathogen** – *Treponema pallidum*

**Matrix** – Urine and/or Physiological Buffer

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

## VANCOMYCIN RESISTANT ENTEROCOCCI (VRE)

VRE21

Designed to evaluate the ability to detect and determine different VRE in clinically relevant sample types using molecular methods.

	Available Format(s)
Catalogue Number	QAB134163_1
Total Number of Challenges	1
Number of Samples	10
Distribution / Testing Period	Q3

### Specifications

**Target Pathogen** – *Vancomycin Resistant Enterococci*

**Matrix** – Microbiological medium and/or Transport Medium

**Sample Volume** – 0.5 ml

**Analysis Type** – Molecular typing

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## FUNGAL EQA PROGRAMMES

### ASPERGILLUS SPP.

ASPDNA21

Designed to evaluate the ability to detect *Aspergillus* species using molecular methods.

	Available Format(s)
Catalogue Number	QAF104140_1
Total Number of Challenges	1
Number of Samples	8
Distribution / Testing Period	Q3

### Specifications

**Target Pathogen** – *Aspergillus* species

**Matrix** – Plasma and/or Physiological Buffer and/or Synthetic Sputum

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative. Quantitative for information purposes only

**Format** – Liquid frozen

**Accreditation** – ISO17043

## CANDIDA SPP.

CANDNA21

Designed to evaluate the ability to detect *Candida* species using molecular methods.

	Available Format(s)
Catalogue Number	QAF124151_1
Total Number of Challenges	1
Number of Samples	10
Distribution / Testing Period	Q3

### Specifications

**Target Pathogen** – *Candida* species

**Matrix** – Plasma and/or Physiological Buffer

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## DERMATOPHYTOSIS

DERMA21

Designed to evaluate the ability to detect *dermatophytes* using routine molecular methods.

	Available Format(s)
Catalogue Number	QAF164187_1
Total Number of Challenges	1
Number of Samples	8
Distribution / Testing Period	Q3

### Specifications

**Target Pathogen** – *Dermatophytes*

**Matrix** – Physiological Buffer

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

## PNEUMOCYSTIS JIROVECII PNEUMONIA (PCP)

PCPDNA21

Designed to evaluate the ability to detect *Pneumocystis jirovecii* using molecular methods.

	Available Format(s)
Catalogue Number	QAF114144_1
Total Number of Challenges	1
Number of Samples	10
Distribution / Testing Period	Q3

### Specifications

**Target Pathogen** – *Pneumocystis jirovecii*

**Matrix** – Physiological Buffer

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative and Quantitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## TRICHOMONAS VAGINALIS

TV21

Designed to evaluate the ability to detect *Trichomonas vaginalis* using routine molecular methods.

	Available Format(s)
Catalogue Number	QAP184202_1
Total Number of Challenges	1
Number of Samples	8
Distribution / Testing Period	Q3

### Specifications

**Target Pathogen** – *Trichomonas vaginalis*

**NA Target Source** – Cultured and/or Clinical material

**Matrix** – Transport Medium, Urine and/or Physiological Buffer

**Sample Volume** – 4.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

## TOXOPLASMA GONDII

TGDNA21

Designed to evaluate the ability to detect *Toxoplasma gondii* using molecular methods.

	Available Format(s)	
Catalogue Number	QAP044123_1	QAP044123_2
Total Number of Challenges	1	2
Number of Samples	10	5
Distribution / Testing Period	Q4	Q2 and Q4

### Specifications

**Target Pathogen** – *Toxoplasma gondii*

**Matrix** – Amniotic Fluid and/or Plasma

**Sample Volume** – 2.0 ml

**Analysis Type** – Qualitative

**Format** – Lyophilised

**Accreditation** – ISO17043

---

## MULTI-PATHOGEN/SYNDROMIC PROGRAMMES

### ARTHROPOD-BORNE VIRUSES

ARBO21

Designed to evaluate the ability to detect different Arthropod-borne viruses (including viruses from *Flavi*-, *Toga*-, *Bunya*-, and/or *Reoviridae* families) using routine molecular methods. The panel is designed to represent various clinical scenarios and may include medically important arboviruses such as Tick-borne encephalitis viruses, sandfly fever viruses, Japanese encephalitis viruses, rift valley fever viruses, Usutu virus, Murray Valley encephalitis virus and St. Louis encephalitis virus.

	Available Format(s)
Catalogue Number	QAM194206_1
Total Number of Challenges	1
Number of Samples	10
Distribution / Testing Period	Q4

### Specifications

**Target Pathogen** – Tick-borne encephalitis viruses, sandfly fever viruses, Japanese encephalitis viruses, rift valley fever viruses, Usutu virus, Murray Valley encephalitis virus and St. Louis encephalitis virus

**NA Target Source** – Cultured and/or Clinical material

**Matrix** – Transport Medium

**Sample Volume** – 1 ml

**Analysis Type** – Qualitative. Quantitative for information purposes only

**Format** – Lyophilised

**Accreditation** – ISO17043

## BACTERIAL GASTROENTERITIS

### GastroB21

Designed to evaluate the ability to detect a range of bacterial pathogens known to cause gastroenteritis using routine molecular diagnostic platforms and procedures. The panel members will resemble clinical samples and may include current clinically relevant strains of *Salmonella*, *Shigella*, *Yersinia*, *E.coli* 0157, *C. difficile* or *Campylobacter* species.

	Available Format(s)	
Catalogue Number	QAB124153_1	QAB124153_2
Total Number of Challenges	1	2
Number of Samples	10	5
Distribution / Testing Period	Q4	Q2 & Q4

### Specifications

**Target Pathogen** – *Salmonella*, *Shigella*, *Yersinia*, *E.coli* 0157, *C. difficile* or *Campylobacter* species

**Matrix** – Synthetic Faecal Matrix and/or Physiological Buffer

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

## CENTRAL NERVOUS SYSTEM I (VIRAL MENINGITIS AND ENCEPHALITIS)

### CNSI21

Designed to evaluate the ability to detect and determine various enterovirus, parechovirus, Herpes simplex virus 1/2, Varicella-Zoster virus and JC virus strains using routine molecular methods. The panel is designed to represent various clinical scenarios.

	Available Format(s)	
Catalogue Number	QAV174195_1	QAV174195_2
Total Number of Challenges	1	2
Number of Samples	10	5
Distribution / Testing Period	Q4	Q2 & Q4

### Specifications

**Target Pathogen** – Various enterovirus, parechovirus, HSV1, HSV2, VZV and JCV

**NA Target Source** – Cultured and/or Clinical material

**Matrix** – Transport Medium

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative. Quantitative for information purposes only

**Format** – Liquid frozen

**Accreditation** – ISO17043

## CENTRAL NERVOUS SYSTEM II (NON-VIRAL MENINGITIS AND ENCEPHALITIS)

### CNSII21

Designed to evaluate the ability to detect and determine various *Listeria* spp., *Neisseria meningitidis*, *Streptococcus pneumoniae*, *Streptococcus agalactiae*, *Escherichia coli* K1, *Aspergillus* spp., *Haemophilus influenzae* and *Cryptococcus* spp. strains using routine molecular methods. The panel is designed to represent various clinical scenarios.

	Available Format(s)	
Catalogue Number	QAM174196_1	QAM174196_2
Total Number of Challenges	1	2
Number of Samples	10	5
Distribution / Testing Period	Q4	Q2 & Q4

### Specifications

**Target Pathogen** – Various *Listeria* spp., *Neisseria meningitidis*, *Streptococcus pneumoniae*, *Streptococcus agalactiae*, *E coli* K1, *Aspergillus* spp., *Haemophilus influenzae* or *Cryptococcus* spp. strains

**NA Target Source** – Cultured and/or Clinical material

**Matrix** – Transport Medium

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative. Quantitative for information purposes only

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## MALDI-TOF

### MALDI21

Designed to evaluate the ability to detect and determine different clinically relevant isolates using MALDI-TOF and other similar mass spectrometry based technologies in the routine microbiology laboratory.

	Available Format(s)
Catalogue Number	QAB124155_1
Total Number of Challenges	1
Number of Samples	10
Distribution / Testing Period	Q3

### Specifications

**Target Pathogen** – Clinically relevant isolates

**Matrix** – Microbiological Medium

**Sample Volume** – 0.5 ml

**Analysis Type** – Typing

**Format** – Liquid frozen

**Accreditation** – ISO17043

## PARASITIC GASTROENTERITIS

### GastroP21

Designed to evaluate the ability to detect a range of parasitic pathogens known to cause gastroenteritis using routine molecular methods. The panel members will resemble clinical samples and may include current clinically relevant strains of *Giardia*, *Cryptosporidium*, *Entamoeba*, *Dientamoeba* and *Blastocystis*.

	Available Format(s)	
Catalogue Number	QAP124154_1	QAP124154_2
Total Number of Challenges	1	2
Number of Samples	10	5
Distribution / Testing Period	Q4	Q2 & Q4

### Specifications

**Target Pathogen** – *Giardia*, *Cryptosporidium*, *Entamoeba*, *Dientamoeba* and *Blastocystis*

**Matrix** – Synthetic Faecal Matrix and/or Physiological Buffer

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## RESPIRATORY I

### RESPI21

Designed to evaluate the ability to detect and determine various Influenza A & B and Respiratory syncytial virus strains. The panel is designed to represent various clinical scenarios.

	Available Format(s)	
Catalogue Number	QAV164188_1	QAV164188_2
Total Number of Challenges	1	2
Number of Samples	10	5
Distribution / Testing Period	Q3	Q1 & Q3

### Specifications

**Target Pathogen** – Influenza A; Influenza B; Respiratory syncytial virus (RSV)

**Matrix** – Transport Medium

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043



## RESPIRATORY II

### RESPII21

Designed to evaluate the ability to detect and determine human metapneumovirus, respiratory adenoviruses, rhinoviruses, coronaviruses, enterovirus and parainfluenza viruses. The panel is designed to represent various clinical scenarios.

	Available Format(s)	
Catalogue Number	QAV164189_1	QAV164189_2
Total Number of Challenges	1	2
Number of Samples	10	5
Distribution / Testing Period	Q3	Q1 & Q3

### Specifications

**Target Pathogen** – Human metapneumovirus; respiratory adenoviruses; rhinoviruses; coronaviruses; enterovirus; parainfluenza viruses

**Matrix** – Transport Medium

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## RESPIRATORY III

### RESPIII21

Designed to evaluate the ability to detect and determine various *Bordetella pertussis*, *Legionella pneumoniae*, *Mycoplasma pneumoniae*, *Streptococcus pneumoniae* or *Haemophilus influenzae* strains using molecular methods. The panel is designed to represent various clinical scenarios.

	Available Format(s)	
Catalogue Number	QAM174193_1	QAM174193_2
Total Number of Challenges	1	2
Number of Samples	10	5
Distribution / Testing Period	Q3	Q1 & Q3

### Specifications

**Target Pathogen** – *Bordetella pertussis*, *Legionella pneumoniae*, *Mycoplasma pneumoniae*, *Streptococcus pneumoniae* or *Haemophilus influenzae* strains.

**Matrix** – Transport Medium

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

## SEPSIS

### SEPSIS21

Designed to evaluate a range of pathogens associated with sepsis such as *Staphylococcus*, *Serratia*, *Escherichia coli*, *Enterococcus*, *Streptococcus*, *Klebsiella*, coagulase-negative *Staphylococcus*, *Pseudomonas* and *Candida* spp. using molecular methods.

	Available Format(s)
Catalogue Number	QAB164178_1
Total Number of Challenges	1
Number of Samples	10
Distribution / Testing Period	Q4

### Specifications

**Target Pathogen** – *Staphylococcus*, *Serratia*, *Escherichia coli*, *Enterococcus*, *Streptococcus*, *Klebsiella*, coagulase-negative *Staphylococcus*, *Pseudomonas* and *Candida* spp.

**Matrix** – Whole Blood and/or Plasma and/or Transport Medium

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## SEXUALLY TRANSMITTED INFECTIONS I

### STI\_I21

Designed to evaluate the ability to detect a range of sexually transmitted infections known to cause disease using routine molecular methods. The panel members will resemble clinical samples and may include current clinically relevant strains of *Mycoplasma genitalium*, *Mycoplasma hominis*, *Trichomonas vaginalis*, *Ureaplasma urealyticum* and *Gardnerella vaginalis*.

	Available Format(s)	
Catalogue Number	QAB154177_1	QAB154177_2
Total Number of Challenges	1	2
Number of Samples	10	5
Distribution / Testing Period	Q3	Q2 & Q3

### Specifications

**Target Pathogen** – *Mycoplasma genitalium*, *Mycoplasma hominis*, *Trichomonas vaginalis*, *Ureaplasma urealyticum* and *Gardnerella vaginalis*

**Matrix** – Urine and/or Physiological Buffer

**Sample Volume** – 4.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

## SEXUALLY TRANSMITTED INFECTIONS II

### STI\_II21

Designed to evaluate the ability to detect a range of sexually transmitted infections known to cause disease using routine molecular methods. The panel members will resemble clinical samples and may include current clinically relevant strains of *Chlamydia trachomatis*, *Neisseria gonorrhoea*, *Treponema pallidum* and Herpes Simplex Virus (HSV) strains.

	Available Format(s)	
Catalogue Number	QAM174201_1	QAM174201_2
Total Number of Challenges	1	2
Number of Samples	10	5
Distribution / Testing Period	Q3	Q2 & Q3

### Specifications

**Target Pathogen** – *Chlamydia trachomatis*, *Neisseria gonorrhoea*, *Treponema pallidum* and HSV

**Matrix** – Urine and/or Physiological Buffer

**Sample Volume** – 4.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## TRANSPLANTATION (VIRAL)

### TRANS21

Designed to evaluate the ability to detect and determine various cytomegalovirus, Epstein-Barr virus, Human herpes virus 6, BK virus, B19 virus and adenovirus strains. The panel is designed to represent various clinical scenarios. Participating laboratories will be expected to test each panel using their appropriate molecular methods and to report their individual test results to QCMD.

	Available Format(s)	
Catalogue Number	QAM174198_1	QAM174198_2
Total Number of Challenges	1	2
Number of Samples	10	5
Distribution / Testing Period	Q3	Q2 & Q4

### Specifications

**Target Pathogen** – Various EBV, HHV6, BKV, B19 and ADV

**NA Target Source** – Cultured and/or Clinical material

**Matrix** – Plasma and/or Transport Medium

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative & Quantitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

## VIRAL GASTROENTERITIS

### GastroV21

Designed to evaluate the ability to detect a range of viral pathogens known to cause gastroenteritis using routine molecular methods. The panel members will resemble clinical samples and may include current clinically relevant strains of norovirus, rotavirus, astrovirus, sapovirus and adenovirus.

	Available Format(s)	
Catalogue Number	QAV124152_1	QAV124152_2
Total Number of Challenges	1	2
Number of Samples	10	5
Distribution / Testing Period	Q4	Q2 & Q4

### Specifications

**Target Pathogen** – norovirus, rotavirus, astrovirus, sapovirus and adenovirus

**Matrix** – Synthetic Faecal Matrix and/or Physiological Buffer

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## VIRAL EQA PROGRAMMES

### ADENOVIRUS (ADV)

#### ADVDNA21

Designed to evaluate the ability to detect Adenovirus using molecular methods.

	Available Format(s)	
Catalogue Number	QAV054133_1	QAV054133_2
Total Number of Challenges	1	2
Number of Samples	10	5
Distribution / Testing Period	Q3	Q2 and Q3

### Specifications

**Target Pathogen** – Adenovirus

**Matrix** – Transport Medium and/or Plasma

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative & Quantitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

## B19 VIRUS

B19DNA21

Designed to evaluate the ability to detect and quantitate B19 virus using molecular methods.

	Available Format(s)	
Catalogue Number	QAV034116_1	QAV034116_2
Total Number of Challenges	1	2
Number of Samples	8	4
Distribution / Testing Period	Q3	Q1 and Q3

### Specifications

**Target Pathogen** – B19 virus

**Matrix** – Plasma

**Units of Measurement** – The primary unit is IU/ml however other units will be accepted

**Sample Volume** – 1.2 ml

**Analysis Type** – Qualitative & Quantitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## BK VIRUS (BKV)

BKDNA21

Designed to evaluate the ability to detect and quantitate various types of BK virus (BKV) and ensure the reliable quantification of BKV viral load using molecular methods.

	Available Format(s)	
Catalogue Number	QAV144166_1	QAV144166_2
Total Number of Challenges	1	2
Number of Samples	10	5
Distribution / Testing Period	Q3	Q2 and Q3

### Specifications

**Target Pathogen** – BK virus

**Matrix** – Transport Medium and/or Plasma and/or Urine

**Units of Measurement** – The primary unit is IU/ml however other units will be accepted

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative & Quantitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

## CHIKUNGUNYA VIRUS (CHIKV)

CHIKV21

Designed to evaluate the ability to detect chikungunya virus using molecular methods.

	Available Format(s)
Catalogue Number	QAV154175_1
Total Number of Challenges	1
Number of Samples	10
Distribution / Testing Period	Q4

### Specifications

**Target Pathogen** – Chikungunya virus

**Matrix** – Transport Medium

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative. Quantitative for information purposes only

**Format** – Lyophilised

**Accreditation** – ISO17043

---

## CORONAVIRUS (CoV)

CVRNA21

Designed to evaluate the ability to detect coronavirus and different coronavirus genotypes using molecular methods.

	Available Format(s)
Catalogue Number	QAV064137_1
Total Number of Challenges	1
Number of Samples	10
Distribution / Testing Period	Q2

### Specifications

**Target Pathogen** – Coronavirus

**Matrix** – Transport Medium

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

## CYTOMEGALOVIRUS (CMV)

### CMVDNA21

Designed to evaluate the ability to detect and quantitate human cytomegalovirus (CMV) using molecular methods.

	Available Format(s)	
Catalogue Number	QAV014120_1	QAV014120_2
Total Number of Challenges	1	2
Number of Samples	10	5
Distribution / Testing Period	Q3	Q2 and Q3

### Specifications

**Target Pathogen** – Cytomegalovirus (CMV)

**Matrix** – Plasma

**Units of Measurement** – The primary unit is IU/ml however other units will be accepted

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative & Quantitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## CYTOMEGALOVIRUS (CMV) DRIED BLOOD SPOTS

### CMVDBS21

Designed to evaluate the ability to detect human cytomegalovirus (CMV) from dried blood spots using molecular methods.

	Available Format(s)
Catalogue Number	QAV064127_1
Total Number of Challenges	1
Number of Samples	8
Distribution / Testing Period	Q4

### Specifications

**Target Pathogen** – Cytomegalovirus (CMV)

**Matrix** – Dried Blood Spots

**Units of Measurement** – The primary unit is IU/ml however other units will be accepted

**Sample Volume** – 2 x 50µl

**Analysis Type** – Qualitative. Quantitative for information purposes only

**Format** – Dried blood spot

**Accreditation** – ISO17043

## CYTOMEGALOVIRUS (CMV) DRUG RESISTANCE

CMVDR21

Designed to evaluate the ability to detect CMV drug resistant mutations in the kinase UL97 and polymerase UL54 genes using molecular sequencing techniques.

	Available Format(s)
Catalogue Number	QAV144169_1
Total Number of Challenges	1
Number of Samples	5
Distribution / Testing Period	Q2

### Specifications

**Target Pathogen** – Cytomegalovirus (CMV) Drug Resistance

**Matrix** – Plasma and/or Physiological Buffer

**Sample Volume** – 1.0 ml

**Analysis Type** – Sequence analysis

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## CYTOMEGALOVIRUS (CMV) WHOLE BLOOD

CMVWB21

Designed to evaluate the ability to detect and quantitate CMV from whole blood samples using molecular methods.

	Available Format(s)	
Catalogue Number	QAV124150_1	QAV124150_2
Total Number of Challenges	1	2
Number of Samples	10	5
Distribution / Testing Period	Q3	Q2 and Q3

### Specifications

**Target Pathogen** – Cytomegalovirus (CMV)

**Matrix** – Whole Blood

**Units of Measurement** – The primary unit is IU/ml however other units will be accepted

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative & Quantitative

**Format** – Liquid frozen

**Accreditation** – ISO17043



## DENGUE VIRUS (DENV)

DENVRNA21

Designed to evaluate the ability to detect Dengue virus and ability to distinguish dengue virus from other flaviviruses using molecular methods.

	Available Format(s)
Catalogue Number	QAV114148_1
Total Number of Challenges	1
Number of Samples	10
Distribution / Testing Period	Q4

### Specifications

**Target Pathogen** – Dengue virus (DENV)

**Matrix** – Transport Medium

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative. Quantitative for information purposes only

**Format** – Lyophilised

**Accreditation** – ISO17043

---

## ENTEROVIRUS (EV)

EVRNA21

Designed to evaluate the ability to detect and quantitate different types of enterovirus (EV) using molecular methods.

	Available Format(s)	
Catalogue Number	QAV984104_1	QAV984104_2
Total Number of Challenges	1	2
Number of Samples	10	5
Distribution / Testing Period	Q3	Q1 and Q3

### Specifications

**Target Pathogen** – Enterovirus (EV)

**Matrix** – Transport Medium

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative. Quantitative for information purposes only

**Format** – Liquid frozen

**Accreditation** – ISO17043

## ENTEROVIRUS TYPING (EV)

EVTP21

Designed to evaluate the ability to correctly identify specific enterovirus (EV) types using routine molecular method and procedures.

	Available Format(s)
Catalogue Number	QAV164185_1
Total Number of Challenges	1
Number of Samples	8
Distribution / Testing Period	Q1

### Specifications

**Target Pathogen** – Enterovirus (EV)

**Matrix** – Transport Medium

**Sample Volume** – 1.0 ml

**Analysis Type** – Molecular typing

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## EPSTEIN-BARR VIRUS (EBV)

EBVDNA21

Designed to evaluate the ability to detect and quantitate Epstein-Barr virus (EBV) in plasma samples using molecular methods.

	Available Format(s)	
Catalogue Number	QAV024121_1	QAV024121_2
Total Number of Challenges	1	2
Number of Samples	10	5
Distribution / Testing Period	Q3	Q2 and Q3

### Specifications

**Target Pathogen** – Epstein-Barr virus (EBV)

**Matrix** – Transport Medium and/or Plasma

**Units of Measurement** – The primary unit is IU/ml however other units will be accepted

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative & Quantitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

## EPSTEIN-BARR VIRUS (EBV) WHOLE BLOOD

EBVWB21

Designed to evaluate the ability to detect and quantitate Epstein-Barr virus (EBV) in whole blood samples using molecular methods.

	Available Format(s)	
Catalogue Number	QAV134161_1	QAV134161_2
Total Number of Challenges	1	2
Number of Samples	10	5
Distribution / Testing Period	Q3	Q2 and Q3

### Specifications

**Target Pathogen** – Epstein-Barr virus (EBV)

**Matrix** – Whole Blood

**Units of Measurement** – The primary unit is IU/ml however other units will be accepted

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative & Quantitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## HEPATITIS A VIRUS (HAV)

HAVRNA21

Designed to evaluate the ability to detect Hepatitis A virus (HAV) using molecular methods.

	Available Format(s)	
Catalogue Number	QAV124156_1	QAV124156_2
Total Number of Challenges	1	2
Number of Samples	8	4
Distribution / Testing Period	Q3	Q1 and Q3

### Specifications

**Target Pathogen** – Hepatitis A virus (HAV)

**Matrix** – Plasma

**Sample Volume** – 1.2 ml

**Analysis Type** – Qualitative. Quantitative for information purposes only

**Format** – Liquid frozen

**Accreditation** – ISO17043

## HEPATITIS B VIRUS (HBV)

HBVDNA21

Designed to evaluate the ability to detect and quantitate Hepatitis B virus (HBV) and different HBV genotypes using molecular methods.

	Available Format(s)		
Catalogue Number	QAV994110_1	QAV994110_2	QAV994110_4
Total Number of Challenges	1	2	4
Number of Samples	8	4	4
Distribution / Testing Period	Q3	Q1 and Q3	Q1, Q2, Q3 and Q4

### Specifications

**Target Pathogen** – Hepatitis B virus (HBV)

**Matrix** – Plasma

**Units of Measurement** – The primary unit is IU/ml however other units will be accepted

**Sample Volume** – 1.2 ml

**Analysis Type** – Qualitative & Quantitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## HEPATITIS B VIRUS (HBV) DRUG RESISTANCE

HBVDR21

Designed to evaluate the ability to detect drug resistant mutations in the Hepatitis B virus (HBV) DNA polymerase gene using sequencing techniques and/or LiPA technology.

	Available Format(s)
Catalogue Number	QAV124160_1
Total Number of Challenges	1
Number of Samples	5
Distribution / Testing Period	Q3

### Specifications

**Target Pathogen** – Hepatitis B virus (HBV) Drug Resistance Mutations

**Matrix** – Plasma

**Sample Volume** – 1.0 ml

**Analysis Type** – Sequence Analysis

**Format** – Liquid frozen

**Accreditation** – ISO17043

## HEPATITIS B VIRUS (HBV) GENOTYPING

HBVGT21

Designed to evaluate the ability to correctly identify Hepatitis B virus (HBV) genotypes using molecular methods.

	Available Format(s)
Catalogue Number	QAV064118_1
Total Number of Challenges	1
Number of Samples	8
Distribution / Testing Period	Q1

### Specifications

**Target Pathogen** – Hepatitis B virus (HBV) Genotyping

**Matrix** – Plasma

**Sample Volume** – 1.2 ml

**Analysis Type** – Molecular typing

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## HEPATITIS C VIRUS (HCV)

HCVRNA21

Designed to evaluate the ability to detect and quantitate Hepatitis C virus (HCV) RNA and different HCV genotypes using molecular methods.

	Available Format(s)		
Catalogue Number	QAV994112_1	QAV994112_2	QAV994112_4
Total Number of Challenges	1	2	4
Number of Samples	8	4	4
Distribution / Testing Period	Q3	Q1 and Q3	Q1, Q2, Q3 and Q4

### Specifications

**Target Pathogen** – Hepatitis C virus (HCV)

**Matrix** – Plasma

**Units of Measurement** – The primary unit is IU/ml however other units will be accepted

**Sample Volume** – 1.2 ml

**Analysis Type** – Qualitative & Quantitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

## HEPATITIS C VIRUS (HCV) DRUG RESISTANCE

HCVDR21

Designed to evaluate the ability to detect drug resistant mutations in the Hepatitis C virus (HCV) genotypes 1 and 3 (NS3 and NS5a regions) using sequencing techniques.

	Available Format(s)
Catalogue Number	QAV134167_1
Total Number of Challenges	1
Number of Samples	5
Distribution / Testing Period	Q3

### Specifications

**Target Pathogen** – Hepatitis C virus (HCV) Drug Resistance Mutations

**Matrix** – Plasma

**Sample Volume** – 1.0 ml

**Analysis Type** – Sequence Analysis

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## HEPATITIS C VIRUS (HCV) GENOTYPING

HCVGT21

Designed to evaluate the ability to correctly genotype Hepatitis C virus (HCV) RNA using molecular methods.

	Available Format(s)
Catalogue Number	QAV034117_1
Total Number of Challenges	1
Number of Samples	8
Distribution / Testing Period	Q1

### Specifications

**Target Pathogen** – Hepatitis C virus (HCV)

**Matrix** – Plasma

**Sample Volume** – 1.2 ml

**Analysis Type** – Molecular typing

**Format** – Liquid frozen

**Accreditation** – ISO17043

## HEPATITIS D VIRUS (HDV)

HDV21

Designed to evaluate the ability to detect Hepatitis D virus (HDV) using molecular methods.

	Available Format(s)
Catalogue Number	QAV144170_1
Total Number of Challenges	1
Number of Samples	8
Distribution / Testing Period	Q3

### Specifications

**Target Pathogen** – Hepatitis D virus (HDV)

**Matrix** – Plasma

**Sample Volume** – 1.2 ml

**Analysis Type** – Qualitative & Quantitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## HEPATITIS E VIRUS (HEV)

HEVRNA21

Designed to evaluate the ability to detect Hepatitis E virus (HEV) using molecular methods.

	Available Format(s)
Catalogue Number	QAV124157_1
Total Number of Challenges	1
Number of Samples	8
Distribution / Testing Period	Q3

### Specifications

**Target Pathogen** – Hepatitis E virus (HEV)

**Matrix** – Plasma

**Sample Volume** – 0.6 ml

**Analysis Type** – Qualitative & Quantitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

## HERPES SIMPLEX VIRUS 1 & 2 (HSV)

### HSV DNA21

Designed to evaluate the ability to detect different types and concentrations of herpes simplex virus (HSV) using molecular methods.

	Available Format(s)	
Catalogue Number	QAV994105_1	QAV994105_2
Total Number of Challenges	1	2
Number of Samples	10	5
Distribution / Testing Period	Q3	Q1 and Q3

### Specifications

**Target Pathogen** – Herpes simplex virus 1 & 2 (HSV)

**Matrix** – Transport Medium and/or Synthetic CSF

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative. Quantitative for information purposes only

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## HERPES SIMPLEX VIRUS DRUG RESISTANCE

### HSV DR21

Designed to evaluate the ability to detect HSV drug resistance mutations in the HSV thymidine kinase (UL23) and DNA polymerase (UL30) genes using routine molecular methods.

	Available Format(s)	
Catalogue Number	QAV164184_1	
Total Number of Challenges	1	
Number of Samples	5	
Distribution / Testing Period	Q1	

### Specifications

**Target Pathogen** – HSV drug resistance mutations

**Matrix** – Transport Medium

**Sample Volume** – 1.0 ml

**Analysis Type** – Sequence Analysis

**Format** – Liquid frozen

**Accreditation** – ISO17043



## HUMAN HERPES VIRUS 6 (HHV6)

HHV6DNA21

Designed to evaluate the ability to detect various types of Human herpes virus 6 (HHV6) and quantitate HHV6 viral load using molecular methods.

	Available Format(s)	
Catalogue Number	QAV084119_1	QAV084119_2
Total Number of Challenges	1	2
Number of Samples	10	5
Distribution / Testing Period	Q3	Q2 and Q3

### Specifications

**Target Pathogen** – Human herpes virus 6 (HHV6)

**Matrix** – Transport Medium and/or Plasma

**Units of Measurement** – The primary unit is IU/ml however other units will be accepted

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative & Quantitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) – DNA

HIVDNA21

Designed to evaluate the ability to detect Human Immunodeficiency virus type 1 (HIV-1) pro-viral DNA using molecular methods.

	Available Format(s)	
Catalogue Number	QAV034114_1	QAV034114_2
Total Number of Challenges	1	2
Number of Samples	8	4
Distribution / Testing Period	Q3	Q1 and Q3

### Specifications

**Target Pathogen** – Human Immunodeficiency virus type 1 (HIV-1) – DNA

**Matrix** – Physiological Buffer

**Sample Volume** – 0.1 ml

**Analysis Type** – Qualitative. Quantitative for information purposes only

**Format** – Liquid frozen

**Accreditation** – ISO17043

## HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) – DRUG RESISTANCE

HIVDR21

Designed to evaluate the ability to detect drug resistant mutations in the HIV-1 protease and reverse transcriptase genes using molecular sequencing techniques.

	Available Format(s)
Catalogue Number	QAV024131_1
Total Number of Challenges	1
Number of Samples	5
Distribution / Testing Period	Q3

### Specifications

**Target Pathogen** – Human Immunodeficiency virus type 1 (HIV-1) – Drug Resistance Mutations

**Matrix** – Plasma

**Sample Volume** – 1.0 ml

**Analysis Type** – Sequence Analysis

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) – DRUG RESISTANCE (INTEGRASE)

HIVDRint21

Designed to evaluate the ability to detect drug resistant mutations in the HIV-1 integrase gene using molecular sequencing techniques.

	Available Format(s)
Catalogue Number	QAV114146_1
Total Number of Challenges	1
Number of Samples	5
Distribution / Testing Period	Q3

### Specifications

**Target Pathogen** – Human Immunodeficiency virus type 1 (HIV-1) – Drug Resistance (Integrase) Mutations

**Matrix** – Plasma

**Sample Volume** – 1.0 ml

**Analysis Type** – Sequence Analysis

**Format** – Liquid frozen

**Accreditation** – ISO17043

## HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) – RNA

HIVRNA21

Designed to evaluate the ability to detect and quantitate human immunodeficiency virus (HIV) RNA and different HIV genotypes using molecular methods.

	Available Format(s)		
Catalogue Number	QAV994108_1	QAV994108_2	QAV994108_4
Total Number of Challenges	1	2	4
Number of Samples	8	4	4
Distribution / Testing Period	Q3	Q1 and Q3	Q1, Q2, Q3 and Q4

### Specifications

**Target Pathogen** – Human Immunodeficiency virus type 1 (HIV-1) – RNA

**Matrix** – Plasma

**Units of Measurement** – The primary unit is IU/ml however other units will be accepted

**Sample Volume** – 1.2 ml

**Analysis Type** – Qualitative & Quantitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## HUMAN METAPNEUMOVIRUS (MPV)

MPV21

Designed to evaluate the ability to detect human metapneumovirus (MPV) and different human MPV types using molecular methods.

	Available Format(s)
Catalogue Number	QAV054135_1
Total Number of Challenges	1
Number of Samples	8
Distribution / Testing Period	Q2

### Specifications

**Target Pathogen** – Human metapneumovirus (MPV)

**Matrix** – Transport Medium

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

## HUMAN PAPILLOMAVIRUS (HPV) – PreservCyt

HPVPRES21

Designed to evaluate the ability to detect different high risk Human Papillomavirus (HPV) types within a PreservCyt® matrix using molecular methods.

	Available Format(s)	
Catalogue Number	QAV094130_1	QAV094130_2
Total Number of Challenges	1	2
Number of Samples	12	6
Distribution / Testing Period	Q4	Q2 and Q4

### Specifications

**Target Pathogen** – Human Papillomavirus (HPV) – PreservCyt®

**Matrix** – Transport Medium (PreservCyt®)

**Sample Volume** – 4.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid ready-to-use

**Accreditation** – ISO17043

---

## HUMAN PAPILLOMAVIRUS (SUREPATH)

HPVSURE21

Designed to evaluate the ability to detect different high-risk Human Papillomavirus (HPV) types within a SurePath™ matrix using routine molecular methods.

	Available Format(s)
Catalogue Number	QAV184204_1
Total Number of Challenges	1
Number of Samples	12
Distribution / Testing Period	Q4

### Specifications

**Target Pathogen** – Human papillomavirus

**NA Target Source** – Clinical material and/or cell lines containing HPV

**Matrix** – Transport Medium (SurePath)

**Sample Volume** – 2.0 ml

**Analysis Type** – Qualitative

**Format** – Lyophilised

**Accreditation** – ISO17043

## INFLUENZA A & B VIRUS (FLU)

INFRNA21

Designed to evaluate the ability to detect influenza virus RNA and distinguish Influenza virus types A and B using molecular methods.

	Available Format(s)	
Catalogue Number	QAV054134_1	QAV054134_2
Total Number of Challenges	1	2
Number of Samples	10	5
Distribution / Testing Period	Q4	Q2 and Q4

### Specifications

**Target Pathogen** – Influenza A & B virus

**Matrix** – Transport Medium

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## INFLUENZA TYPING

INFTP21

Designed to evaluate the ability to detect different influenza virus subtypes in addition to the typing and subtyping of influenza viruses using molecular methods.

	Available Format(s)
Catalogue Number	QAV064138_1
Total Number of Challenges	1
Number of Samples	8
Distribution / Testing Period	Q4

### Specifications

**Target Pathogen** – Influenza Typing

**Matrix** – Transport Medium

**Sample Volume** – 1.0 ml

**Analysis Type** – Molecular typing

**Format** – Liquid frozen

**Accreditation** – ISO17043

## JC VIRUS (JCV)

JCDNA21

Designed to evaluate the ability to detect and quantitate various types of JC virus (JCV) using molecular methods.

	Available Format(s)	
Catalogue Number	QAV074106_1	QAV074106_2
Total Number of Challenges	1	2
Number of Samples	10	5
Distribution / Testing Period	Q3	Q2 and Q3

### Specifications

**Target Pathogen** – JC virus (JCV)

**Matrix** – Transport Medium and/or Plasma

**Units of Measurement** – The primary unit is IU/ml however other units will be accepted

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative & Quantitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## MEASLES/MUMPS

MM21

Designed to evaluate the ability to detect mumps and/or measles using routine molecular methods.

	Available Format(s)	
Catalogue Number	QAV144171_1	
Total Number of Challenges	1	
Number of Samples	10	
Distribution / Testing Period	Q3	

### Specifications

**Target Pathogen** – Mumps and/or Measles

**Matrix** – Transport Medium

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

## MERS CORONAVIRUS (MERS-CoV)

MERS21

Designed to evaluate the ability to detect and determine MERS-CoV from other coronaviruses.

	Available Format(s)
Catalogue Number	QAV154181_1
Total Number of Challenges	1
Number of Samples	8
Distribution / Testing Period	Q2

### Specifications

**Target Pathogen** – MERS coronavirus (MERS-CoV)

**Matrix** – Transport Medium

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## NOROVIRUS (NV)

NVRNA21

Designed to evaluate the ability to detect norovirus and different norovirus (NV) genogroups using molecular methods.

	Available Format(s)	
Catalogue Number	QAV084139_1	QAV084139_2
Total Number of Challenges	1	2
Number of Samples	10	5
Distribution / Testing Period	Q4	Q2 and Q4

### Specifications

**Target Pathogen** – Norovirus (NV)

**Matrix** – Transport Medium and/or Physiological Buffer and/or Synthetic Faecal Matrix

**Sample Volume** – 1.0 ml VTM, 0.1ml Buffer

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

## PARAINFLUENZA VIRUS (PIV)

PINFRNA21

Designed to evaluate the ability to detect Parainfluenza virus and different Parainfluenza virus (PIV) types using molecular methods.

	Available Format(s)
Catalogue Number	QAV064136_1
Total Number of Challenges	1
Number of Samples	10
Distribution / Testing Period	Q2

### Specifications

**Target Pathogen** – Parainfluenza virus (PIV)

**Matrix** – Transport Medium

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## PARECHOVIRUS (HPeV)

PeVRNA21

Designed to evaluate the ability to detect Parainfluenza virus and different Parainfluenza virus types using molecular methods.

	Available Format(s)	
Catalogue Number	QAV114145_1	QAV114145_2
Total Number of Challenges	1	2
Number of Samples	10	5
Distribution / Testing Period	Q3	Q1 and Q3

### Specifications

**Target Pathogen** – Parechovirus (HPeV)

**Matrix** – Transport Medium

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043



## RESPIRATORY SYNCYTIAL VIRUS (RSV)

RSV21

Designed to evaluate the ability to detect different types of Respiratory syncytial virus (RSV) using molecular methods.

	Available Format(s)	
Catalogue Number	QAV054142_1	QAV054142_2
Total Number of Challenges	1	2
Number of Samples	10	5
Distribution / Testing Period	Q4	Q2 and Q4

### Specifications

**Target Pathogen** – Respiratory syncytial virus (RSV)

**Matrix** – Transport Medium

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## RHINOVIRUS (RV)

RVRNA21

Designed to evaluate the ability to detect rhinovirus and different rhinovirus (RV) genotypes using molecular methods.

	Available Format(s)	
Catalogue Number	QAV064143_1	
Total Number of Challenges	1	
Number of Samples	10	
Distribution / Testing Period	Q2	

### Specifications

**Target Pathogen** – Rhinovirus (RV)

**Matrix** – Transport Medium

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

## SARS-COV-2

### SCV2\_21

Designed to assess the proficiency of laboratories in the detection and differentiation of SARS-CoV-2 and different coronavirus genotypes.

	Available Format(s)			
Catalogue Number	QAV204215_1A	QAV204215_1B	QAV204215_1C	QAV204215_1D
Total Number of Challenges	1	1	1	1
Number of Samples	5	5	5	5
Distribution / Testing Period	Q1	Q2	Q3	Q4

### Specifications

**Target Pathogen** – SARS-CoV-2

**Matrix** – Transport Medium

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## TORQUE TENO VIRUS

### TTV21

Designed to evaluate the ability to detect Torque teno virus (TTV) using routine molecular diagnostic platforms and procedures.

	Available Format(s)
Catalogue Number	QAV184203_1
Total Number of Challenges	1
Number of Samples	6
Distribution / Testing Period	Q4

### Specifications

**Target Pathogen** – Torque teno virus

**NA Target Source** – Cultured and/or Clinical material

**Matrix** – Transport Medium and/or Plasma

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

**Accreditation** – ISO17043

## VARICELLA-ZOSTER VIRUS (VZV)

VZVDNA21

Designed to evaluate the ability to detect different types and concentrations of Varicella-Zoster virus (VZV) using molecular methods.

	Available Format(s)	
Catalogue Number	QAV034103_1	QAV034103_2
Total Number of Challenges	1	2
Number of Samples	10	5
Distribution / Testing Period	Q3	Q1 and Q3

### Specifications

**Target Pathogen** – Varicella-Zoster virus (VZV)

**Matrix** – Transport Medium and/or Synthetic CSF

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative. Quantitative for information purposes only

**Format** – Liquid frozen

**Accreditation** – ISO17043

---

## WEST NILE VIRUS (WNV)

WNVRNA21

Designed to evaluate the ability to detect West Nile virus and distinguish West Nile virus from other flaviviruses using molecular methods.

	Available Format(s)	
Catalogue Number	QAV104141_1	
Total Number of Challenges	1	
Number of Samples	10	
Distribution / Testing Period	Q4	

### Specifications

**Target Pathogen** – West Nile virus (WNV)

**Matrix** – Transport Medium

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative. Quantitative for information purposes only

**Format** – Lyophilised

**Accreditation** – ISO17043

## YELLOW FEVER VIRUS

YFV21

Designed to evaluate the ability to detect Yellow fever virus and to distinguish Yellow fever virus from other flaviviruses using routine molecular methods.

	Available Format(s)
Catalogue Number	QAM194207_1
Total Number of Challenges	1
Number of Samples	8
Distribution / Testing Period	Q4

### Specifications

**Target Pathogen** – Yellow fever virus

**NA Target Source** – Cultured and/or Clinical material

**Matrix** – Transport Medium

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative. Quantitative for information purposes only

**Format** – Lyophilised

**Accreditation** – ISO17043

---

## ZIKA VIRUS

ZIKA21

Designed to evaluate the ability to detect Zika virus and determine the proficiency of laboratories in distinguishing Zika virus from other flaviviruses.

	Available Format(s)
Catalogue Number	QAV164186_1
Total Number of Challenges	1
Number of Samples	10
Distribution / Testing Period	Q4

### Specifications

**Target Pathogen** – Zika virus

**Matrix** – Transport Medium

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative. Quantitative for information purposes only

**Format** – Lyophilised

**Accreditation** – ISO17043

## PILOT STUDIES

### BABESIA

#### BABESIA21

*Babesia* is a tiny parasite that infects red blood cells. The parasitic infection is usually transmitted by a tick bite. Babesiosis often occurs at the same time as Lyme Disease. The tick that carries the Lyme bacteria can also be infected with the *Babesia* parasite. The QCMD pilot EQA scheme will assess the proficiency of laboratories in the correct detection and identification of *Babesia* species causing human babesiosis.

	Available Format(s)
Catalogue Number	QAP214219_1
Total Number of Challenges	1
Number of Samples	10
Distribution / Testing Period	Q4

#### Specifications

**Target Pathogen** – *Babesia* species

**NA Target Source** – Cultured and/or Clinical material

**Matrix** – Whole Blood

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative. Quantitative for information purposes only

**Format** – Lyophilised

### CHAGAS

#### CHAGAS21

*Trypanosoma cruzi* is the causative agent of Chagas disease. *T. cruzi* is endemic in Mexico and all countries in Central & South America. It is primarily transmitted by triatomine bugs, however, other transmission routes such as transplacental, blood transfusion, organ transplantation and contaminated food are known. The pilot EQA scheme will assess the proficiency of laboratories in the correct detection of *Trypanosoma cruzi*.

	Available Format(s)
Catalogue Number	QAP214217_1
Total Number of Challenges	1
Number of Samples	10
Distribution / Testing Period	Q4

#### Specifications

**Target Pathogen** – *Trypanosoma cruzi*

**NA Target Source** – Cultured and/or Clinical material

**Matrix** – Whole Blood

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative. Quantitative for information purposes only

**Format** – Lyophilised

## FRANCISELLA TULARENSIS

FRATUL21

Tularemia is a severe zoonosis that can affect humans as well as animals. The pathogen occurs in the northern hemisphere (in Europe, the number of human cases is approximately 800 annually, with Sweden and Finland reporting the highest notification rates). The pilot EQA scheme will assess the proficiency of laboratories in the correct detection of *Francisella tularensis*.

	Available Format(s)
Catalogue Number	QAB214220_1
Total Number of Challenges	1
Number of Samples	10
Distribution / Testing Period	Q4

### Specifications

**Target Pathogen** – *Francisella tularensis*

**NA Target Source** – Cultured and/or Clinical material

**Matrix** – Transport Medium and/or Physiological Buffer

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative. Quantitative for information purposes only

**Format** – Lyophilised

---

## HEPATITIS B VIRUS (HBV) DRIED BLOOD SPOTS

HBVDBS21

The pilot EQA scheme is designed to assess the performance of laboratories in the detection of clinically relevant levels of hepatitis B virus (HBV) from dried blood spots.

	Available Format(s)
Catalogue Number	QAV214223_1
Total Number of Challenges	1
Number of Samples	8
Distribution / Testing Period	Q4

### Specifications

**Target Pathogen** – Hepatitis B (HBV)

**Matrix** – Dried Blood Spots

**Sample Volume** – 2 x 50µl

**Analysis Type** – Qualitative. Quantitative for information purposes only

**Format** – Dried blood spot

## HEPATITIS C VIRUS (HCV) DRIED BLOOD SPOTS

HCVDBS21

The pilot EQA scheme is designed to assess the performance of laboratories in the detection of clinically relevant levels of hepatitis C virus (HCV) from dried blood spots.

	Available Format(s)
Catalogue Number	QAV214222_1
Total Number of Challenges	1
Number of Samples	8
Distribution / Testing Period	Q4

### Specifications

**Target Pathogen** – Hepatitis C (HCV)

**Matrix** – Dried Blood Spots

**Sample Volume** – 2 x 50µl

**Analysis Type** – Qualitative. Quantitative for information purposes only

**Format** – Dried blood spot

---

## HUMAN IMMUNODEFICIENCY VIRUS (HIV) DRIED BLOOD SPOTS

HIVDBS21

The pilot EQA scheme is designed to assess the performance of laboratories in the detection of clinically relevant levels of human immunodeficiency virus (HIV) from dried blood spots.

	Available Format(s)
Catalogue Number	QAV214221_1
Total Number of Challenges	1
Number of Samples	8
Distribution / Testing Period	Q4

### Specifications

**Target Pathogen** – Human Immunodeficiency virus (HIV)

**Matrix** – Dried Blood Spots

**Sample Volume** – 2 x 50µl

**Analysis Type** – Qualitative. Quantitative for information purposes only

**Format** – Dried blood spot

## HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 (HIV-2)

HIV2\_21

This pilot study assesses the proficiency of laboratories in detection and quantitation of human immunodeficiency virus type 2 (HIV-2).

	Available Format(s)	
Catalogue Number	QAV204212_1	QAV204212_2
Total Number of Challenges	1	2
Number of Samples	8	4
Distribution / Testing Period	Q3	Q1 & Q3

### Specifications

**Target Pathogen** – Human Immunodeficiency virus (type 2)

**NA Target Source** – Cultured and/or Clinical material

**Matrix** – Plasma

**Sample Volume** – 1.2ml

**Analysis Type** – Qualitative & Quantitative

**Format** – Liquid frozen

---

## MALARIA

MALARIA21

Malaria occurs primarily in tropical and less frequently in subtropical areas. While *P. falciparum* dominates throughout Africa, *P. vivax* is the second most prevalent malaria species in most of Latin American and Asian malaria areas. The range of *P. ovale* is mainly restricted to West African regions while *P. malariae* is found worldwide, but at a lower incidence compared to the other species. The pilot EQA scheme will assess the proficiency of laboratories in the correct detection and identification of Plasmodium species causing human malaria.

	Available Format(s)
Catalogue Number	QAP214218_1
Total Number of Challenges	1
Number of Samples	10
Distribution / Testing Period	Q4

### Specifications

**Target Pathogen** – Plasmodium species

**NA Target Source** – Cultured and/or Clinical material

**Matrix** – Whole Blood

**Sample Volume** – 1.0 ml

**Analysis Type** – Qualitative. Quantitative for information purposes only

**Format** – Lyophilised



## RESPIRATORY I PLUS

### RESPIplus21

The Respiratory I Plus EQA will focus on the molecular detection and determination of various influenza A and B, respiratory syncytial virus strains and SARS-CoV-2. The panel is designed to represent various clinical scenarios. Participating laboratories will be expected to test each panel using their appropriate molecular methods and report their individual test results to QCMD.

	Available Format(s)
Catalogue Number	QAM204216_1
Total Number of Challenges	1
Number of Samples	10
Distribution / Testing Period	Q3

### Specifications

**Target Pathogen** – SARS-CoV-2, Influenza A; Influenza B; Respiratory syncytial virus (RSV)

**NA Target Source** – Cultured and/or Clinical material

**Matrix** – Transport Medium

**Sample Volume** – 1.0ml

**Analysis Type** – Qualitative

**Format** – Liquid frozen

## VIRAL METAGENOMICS NGS

### NGSmeta\_21

This EQA pilot study aims to assess performance of existing metagenomics protocols as currently implemented by participating laboratories. Samples will be provided which will mimic cerebrospinal fluid samples containing known viral pathogens including enterovirus, herpes simplex virus and influenza virus. Performance will be assessed based on the qualitative identification of viruses present in the samples, at the family, genus, species and subtype levels.

	Available Format(s)
Catalogue Number	QAV204213_1
Total Number of Challenges	1
Number of Samples	5
Distribution / Testing Period	Q4

### Specifications

**Target Pathogen** – Enterovirus, herpes simplex virus and influenza virus.

**NA Target Source** – Cultured material

**Matrix** – Synthetic CSF + human cell lines

**Sample Volume** – 1.0ml

**Analysis Type** – Sequence Analysis

**Format** – Liquid frozen

# INDEX

BLOODBORNE VIRUSES	PAGE NUMBER
B19 virus	27
Hepatitis A virus (HAV)	33
Hepatitis B virus (HBV)	34
Hepatitis B virus (HBV) Drug Resistance	34
Hepatitis B virus (HBV) Genotyping	35
Hepatitis C virus (HCV)	35
Hepatitis C virus (HCV) Drug Resistance	36
Hepatitis C virus (HCV) Genotyping	36
Hepatitis D virus (HDV)	37
Hepatitis E virus (HEV)	37
Human Immunodeficiency virus type 1 (HIV-1) DNA	39
Human Immunodeficiency virus type 1 (HIV-1) Drug Resistance	40
Human Immunodeficiency virus type 1 (HIV-1) Drug Resistance (Integrase)	40
Human Immunodeficiency virus type 1 (HIV-1) RNA	41

CENTRAL NERVOUS SYSTEM (CNS) PATHOGENS	PAGE NUMBER
Arthropod-borne viruses	19
BK virus (BKV)	27
<i>Borrelia burgdorferi</i> spp. (Lyme Disease)	05
Central Nervous System I (Viral Meningitis and Encephalitis)	20
Central Nervous System II (Non-viral Meningitis and Encephalitis)	21
Chikungunya virus (CHIKV)	28
Dengue virus (DENV)	31
Enterovirus (EV)	31
Enterovirus Typing (EV)	32
Herpes simplex virus 1 & 2 (HSV)	38
Herpes simplex virus Drug Resistance	38
JC virus (JCV)	44
Measles / Mumps	44
Parechovirus (HPeV)	46
<i>Toxoplasma gondii</i>	19
Varicella-Zoster virus (VZV)	49
West Nile virus (WNV)	49
Zika virus	50

CONGENITAL INFECTIONS	PAGE NUMBER
Cytomegalovirus (CMV) Dried Blood Spots	29
<i>Toxoplasma gondii</i>	19

DRUG RESISTANCE	PAGE NUMBER
Cytomegalovirus (CMV) Drug Resistance	30
Extended Spectrum $\beta$ -lactamase and Carbapenemase	09
Hepatitis B virus (HBV) Drug Resistance	34
Hepatitis C virus (HCV) Drug Resistance	36
Herpes simplex virus Drug Resistance	38
Human Immunodeficiency virus type 1 (HIV-1) Drug Resistance	40
Human Immunodeficiency virus type 1 (HIV-1) Drug Resistance (Integrase)	40
Methicillin Resistant <i>Staphylococcus aureus</i> (MRSA)	11
<i>Mycobacterium tuberculosis</i> Drug Resistance	12
Vancomycin Resistant Enterococci (VRE)	16

EXOTIC/EMERGING DISEASES	PAGE NUMBER
Arthropod-borne viruses	19
Chikungunya virus (CHIKV)	28
Dengue virus (DENV)	31
MERS coronavirus (MERS-CoV)	45

EXOTIC/EMERGING DISEASES	PAGE NUMBER
SARS-CoV-2	48
West Nile virus (WNV)	49
Yellow fever virus	50
Zika virus	50

GASTROINTESTINAL DISEASES	PAGE NUMBER
Adenovirus (ADV)	26
Bacterial Gastroenteritis	20
<i>Clostridium difficile</i> (CD)	08
Diarrheagenic <i>Escherichia coli</i>	08
<i>Helicobacter pylori</i>	10
Norovirus (NV)	45
Parasitic Gastroenteritis	22
Viral Gastroenteritis	26

IMMUNOCOMPROMISED ASSOCIATED INFECTIONS	PAGE NUMBER
<i>Aspergillus</i> spp.	16
BK virus (BKV)	27
<i>Candida</i> spp.	17
Cytomegalovirus (CMV)	29
Cytomegalovirus (CMV) Drug Resistance	30
Cytomegalovirus (CMV) Whole Blood	30
Epstein-Barr virus (EBV)	32
Epstein-Barr virus (EBV) Whole Blood	33
Human herpes virus 6 (HHV6)	39
JC virus (JCV)	44
<i>Pneumocystis jirovecii</i> pneumonia (PCP)	18
Torque teno virus (TTV)	48
<i>Toxoplasma gondii</i>	19
Transplantation (Viral)	25

MULTIPLE PATHOGEN/SYNDROMIC	PAGE NUMBER
Arthropod-borne viruses	19
Bacterial Gastroenteritis	20
Central Nervous System I (Viral Meningitis and Encephalitis)	20
Central Nervous System II (Non-viral Meningitis and Encephalitis)	21
<i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i>	07
MALDI-TOF	21
Parasitic Gastroenteritis	22
Respiratory I	22
Respiratory II	23
Respiratory III	23
Sepsis	24
Sexually Transmitted Infections I	24
Sexually Transmitted Infections II	25
Transplantation (Viral)	25
Viral Gastroenteritis	26

OTHER	PAGE NUMBER
Dermatophytosis	17
Group B <i>Streptococcus</i>	09
<i>Mycoplasma</i> spp. (cell contamination)	14

RESPIRATORY DISEASES	PAGE NUMBER
Adenovirus (ADV)	26
Atypical mycobacterium or non-tuberculosis mycobacterium	04
<i>Bordetella pertussis</i>	05
<i>Chlamydia psittaci</i>	06
<i>Chlamydophila pneumoniae</i>	07
Coronavirus (CoV)	28
Human metapneumovirus (MPV)	41

RESPIRATORY DISEASES	PAGE NUMBER
Influenza A & B virus (FLU)	43
Influenza Typing	43
<i>Legionella pneumophila</i>	10
Measles / Mumps	44
MERS coronavirus (MERS-CoV)	45
<i>Mycobacterium tuberculosis</i> (MTB)	12
<i>Mycobacterium tuberculosis</i> Drug Resistance	12
<i>Mycoplasma pneumoniae</i>	13
Parainfluenza virus (PIV)	46
<i>Pneumocystis jirovecii</i> pneumonia (PCP)	18
Respiratory I	22
Respiratory II	23
Respiratory III	23
Respiratory syncytial virus (RSV)	47
Rhinovirus (RV)	47
SARS-CoV-2	48
Varicella-Zoster virus (VZV)	49

SEXUALLY TRANSMITTED INFECTIONS	PAGE NUMBER
<i>Chlamydia trachomatis</i>	06
<i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i>	07
Herpes simplex virus 1 & 2 (HSV)	38
Herpes simplex virus Drug Resistance	38
Human Papillomavirus (HPV) – PreservCyt	42
Human Papillomavirus (Surepath)	42
<i>Mycoplasma genitalium</i>	13
<i>Neisseria gonorrhoeae</i>	14
Sexually Transmitted Infections I	24
Sexually Transmitted Infections II	25
Syphilis	15
<i>Trichomonas vaginalis</i>	18

SYNDROMIC	PAGE NUMBER
Arthropod-borne viruses	19
Central Nervous System I (Viral Meningitis and Encephalitis)	20
Central Nervous System II (Non-viral Meningitis and Encephalitis)	21
Sepsis	24
Transplantation (Viral)	25

TRANSPLANT ASSOCIATED DISEASES	PAGE NUMBER
Adenovirus (ADV)	26
BK virus (BKV)	27
Cytomegalovirus (CMV)	30
Cytomegalovirus (CMV) Drug Resistance	29
Cytomegalovirus (CMV) Whole Blood	30
Epstein-Barr virus (EBV)	32
Epstein-Barr virus (EBV) Whole Blood	33
Human herpes virus 6 (HHV6)	39
JC virus (JCV)	44
Torque teno virus (TTV)	48
<i>Toxoplasma gondii</i>	19
Transplantation (Viral)	25
Varicella-Zoster virus (VZV)	49

TYPING	PAGE NUMBER
Bacterial 16S Ribosomal RNA	04
Cytomegalovirus (CMV) Drug Resistance	30
Enterovirus Typing (EV)	32
Hepatitis B virus (HBV) Drug Resistance	34
Hepatitis B virus (HBV) Genotyping	35

TYPING	PAGE NUMBER
Hepatitis C virus (HCV) Drug Resistance	36
Hepatitis C virus (HCV) Genotyping	36
Herpes simplex virus Drug Resistance	38
Human Immunodeficiency virus type 1 (HIV-1) Drug Resistance	40
Human Immunodeficiency virus type 1 (HIV-1) Drug Resistance (Integrase)	40
Influenza Typing (HA)	43
MALDI-TOF	21
Methicillin Resistant <i>Staphylococcus aureus</i> (MRSA) Typing	11
<i>Staphylococcus aureus spa</i>	15

## PILOT STUDIES

BLOODBORNE VIRUSES	PAGE NUMBER
Babesia	51
Chagas	51
<i>Francisella tularensis</i>	52
Hepatitis B virus (HBV) Dried Blood Spots	52
Hepatitis C virus (HCV) Dried Blood Spots	53
Human Immunodeficiency virus (HIV) Dried Blood Spots	53
Human Immunodeficiency virus type 2 (HIV-2)	54
Malaria	54

CONGENITAL INFECTIONS	PAGE NUMBER
Chagas	51

DRUG RESISTANCE	PAGE NUMBER
Hepatitis B virus (HBV) Dried Blood Spots	52
Hepatitis C virus (HCV) Dried Blood Spots	53
Human Immunodeficiency virus (HIV) Dried Blood Spots	53
Human Immunodeficiency virus type 2 (HIV-2)	54

EXOTIC/EMERGING DISEASES	PAGE NUMBER
Babesia	51
Chagas	51
<i>Francisella tularensis</i>	52
Malaria	54
Respiratory I Plus	55

IMMUNOCOMPROMISED ASSOCIATED INFECTIONS	PAGE NUMBER
Babesia	51
Chagas	51

MULTIPLE PATHOGEN/SYNDROMIC	PAGE NUMBER
Respiratory I Plus	55

RESPIRATORY DISEASES	PAGE NUMBER
Respiratory I Plus	55
Viral Metagenomics NGS	55

SEXUALLY TRANSMITTED INFECTIONS	PAGE NUMBER
Human Immunodeficiency virus type 2 (HIV-2)	54

TYPING	PAGE NUMBER
Hepatitis B virus (HBV) Dried Blood Spots	52
Hepatitis C virus (HCV) Dried Blood Spots	53
Human Immunodeficiency virus (HIV) Dried Blood Spots	53
Human Immunodeficiency virus type 2 (HIV-2)	54

# APPENDIX

TARGET PATHOGEN							PAGE NUMBER
PROGRAMME CODE	CATALOGUE NUMBER	NO. OF CHALLENGES	PANEL MEMBERS PER CHALLENGE	DISTRIBUTION DATE(S)/ TESTING PERIOD	SHIPPING CONDITIONS	ANALYSIS TYPE	PROGRAMME TYPE
<b>Adenovirus (AVD)</b>							<b>Pg 26</b>
ADVDNA21	QAV054133_1 QAV054133_2	1 2	10 5	Q3 Q2, Q3	Dry-ice	Qualitative & Quantitative	Viral EQA
<b>Arthropod-borne viruses</b>							<b>Pg 19</b>
ARBO21	QAM194206_1	1	10	Q4	Ambient	Qualitative	Multi-Pathogen / Syndromic EQA
<b>Aspergillus spp.</b>							<b>Pg 16</b>
ASPDNA21	QAF104140_1	1	8	Q3	Dry-ice	Qualitative	Fungal EQA
<b>Atypical mycobacterium</b>							<b>Pg 04</b>
NTM21	QAB194208_1	1	10	Q2	Ambient	Qualitative	Bacterial EQA
<b>B19 virus</b>							<b>Pg 27</b>
B19DNA21	QAV034116_1 QAV034116_2	1 2	8 4	Q3 Q1, Q3	Dry-ice	Qualitative & Quantitative	Viral EQA
<b>Babesia</b>							<b>Pg 51</b>
BABESIA21	QAP214219_1	1	10	Q4	Ambient	Qualitative	Pilot Study
<b>Bacterial 16S Ribosomal RNA</b>							<b>Pg 04</b>
B16SrRNA21	QAB164183_1	1	8	Q4	Dry-ice	Typing	Bacterial EQA
<b>Bacterial Gastroenteritis</b>							<b>Pg 20</b>
GastroB21	QAB124153_1 QAB124153_2	1 2	10 5	Q4 Q2 & Q4	Dry-ice	Qualitative	Multi-Pathogen / Syndromic EQA
<b>BK virus (BKV)</b>							<b>Pg 27</b>
BKDNA21	QAV144166_1 QAV144166_2	1 2	10 5	Q3 Q2, Q3	Dry-ice	Qualitative & Quantitative	Viral EQA
<b>Bordetella pertussis</b>							<b>Pg 05</b>
BPDNA21	QAB094132_1	1	10	Q2	Dry-ice	Qualitative	Bacterial EQA
<b>Borrelia burgdorferi spp. (Lyme Disease)</b>							<b>Pg 05</b>
BbDNA21	QAB114147_1	1	10	Q3	Dry-ice	Qualitative	Bacterial EQA
<b>Candida spp.</b>							<b>Pg 17</b>
CANDNA21	QAF124151_1	1	10	Q3	Dry-ice	Qualitative	Fungal EQA
<b>Central Nervous System I (Viral Meningitis and Encephalitis)</b>							<b>Pg 20</b>
CNSI21	QAV174195_1 QAV174195_2	1 2	10 5	Q4 Q2 & Q4	Dry-ice	Qualitative	Multi-Pathogen / Syndromic EQA
<b>Central Nervous System II (Non-viral Meningitis and Encephalitis)</b>							<b>Pg 21</b>
CNSII21	QAM174196_1 QAM174196_2	1 2	10 5	Q4 Q2 & Q4	Dry-ice	Qualitative	Multi-Pathogen / Syndromic EQA
<b>Chagas</b>							<b>Pg 51</b>
CHAGAS21	QAP214217_1	1	10	Q4	Ambient	Qualitative	Pilot Study
<b>Chikungunya virus (CHIKV)</b>							<b>Pg 28</b>
CHIKV21	QAV154175_1	1	10	Q4	Ambient	Qualitative	Viral EQA
<b>Chlamydia psittaci</b>							<b>Pg 06</b>
CPS21	QAB134165_1	1	8	Q2	Dry-ice	Qualitative	Bacterial EQA

TARGET PATHOGEN							PAGE NUMBER
PROGRAMME CODE	CATALOGUE NUMBER	NO. OF CHALLENGES	PANEL MEMBERS PER CHALLENGE	DISTRIBUTION DATE(S)/ TESTING PERIOD	SHIPPING CONDITIONS	ANALYSIS TYPE	PROGRAMME TYPE
<b>Chlamydia trachomatis</b>							<b>Pg 06</b>
CTDNA21	QAB004101_1	1	10	Q3	Dry-ice	Qualitative	Bacterial EQA
	QAB004101_2	2	5	Q1, Q3			
<b>Chlamydia trachomatis and Neisseria gonorrhoeae</b>							<b>Pg 07</b>
CTNg21	QAB174191_1	1	10	Q3	Dry-ice	Qualitative	Bacterial EQA
	QAB174191_2	2	5	Q1, Q3			
<b>Chlamyidophila pneumoniae</b>							<b>Pg 07</b>
CP21	QAB084107_1	1	5	Q2	Dry-ice	Qualitative	Bacterial EQA
<b>Clostridium difficile (CD)</b>							<b>Pg 08</b>
CDDNA21	QAB084125_1	1	10	Q4	Dry-ice	Qualitative	Bacterial EQA
	QAB084125_2	2	5	Q2, Q4			
<b>Coronavirus (CoV)</b>							<b>Pg 28</b>
CVRNA21	QAV064137_1	1	10	Q2	Dry-ice	Qualitative	Viral EQA
<b>Cytomegalovirus (CMV)</b>							<b>Pg 29</b>
CMVDNA21	QAV014120_1	1	10	Q3	Dry-ice	Qualitative & Quantitative	Viral EQA
	QAV014120_2	2	5	Q2, Q3			
<b>Cytomegalovirus (CMV) Dried Blood Spots</b>							<b>Pg 29</b>
CMVDBS21	QAV064127_1	1	8	Q4	Ambient	Qualitative	Viral EQA
<b>Cytomegalovirus (CMV) Drug Resistance</b>							<b>Pg 30</b>
CMVDR21	QAV144169_1	1	5	Q2	Dry-ice	Drug Resistance / Sequencing	Viral EQA
<b>Cytomegalovirus (CMV) Whole Blood</b>							<b>Pg 30</b>
CMVWB21	QAV124150_1	1	10	Q3	Dry-ice	Qualitative & Quantitative	Viral EQA
	QAV124150_2	2	5	Q2, Q3			
<b>Dengue virus (DENV)</b>							<b>Pg 31</b>
DENVRNA21	QAV114148_1	1	10	Q4	Ambient	Qualitative	Viral EQA
<b>Dermatophytosis</b>							<b>Pg 17</b>
DERMA21	QAF164187_1	1	8	Q3	Dry-ice	Qualitative	Fungal EQA
<b>Diarrheagenic Escherichia coli</b>							<b>Pg 08</b>
E.COLI21	QAB154179_1	1	8	Q4	Dry-ice	Typing	Bacterial EQA
<b>Enterovirus (EV)</b>							<b>Pg 31</b>
EVRNA21	QAV984104_1	1	10	Q3	Dry-ice	Qualitative	Viral EQA
	QAV984104_2	2	5	Q1, Q3			
<b>Enterovirus Typing (EV)</b>							<b>Pg 32</b>
EVTP21	QAV164185_1	1	8	Q1	Dry-ice	Typing	Viral EQA
<b>Epstein-Barr virus (EBV)</b>							<b>Pg 32</b>
EBVDNA21	QAV024121_1	1	10	Q3	Dry-ice	Qualitative & Quantitative	Viral EQA
	QAV024121_2	2	5	Q2, Q3			
<b>Epstein-Barr virus (EBV) Whole Blood</b>							<b>Pg 33</b>
EBVWB21	QAV134161_1	1	10	Q3	Dry-ice	Qualitative & Quantitative	Viral EQA
	QAV134161_2	2	5	Q2, Q3			
<b>Extended Spectrum <math>\beta</math>-lactamase and Carbapenemase</b>							<b>Pg 09</b>
ESBL21	QAB134162_1	1	8	Q3	Dry-ice	Typing	Bacterial EQA
<b>Francisella tularensis</b>							<b>Pg 52</b>
FRATUL21	QAB214220_1	1	10	Q4	Ambient	Qualitative	Pilot Study

TARGET PATHOGEN							PAGE NUMBER
PROGRAMME CODE	CATALOGUE NUMBER	NO. OF CHALLENGES	PANEL MEMBERS PER CHALLENGE	DISTRIBUTION DATE(S)/ TESTING PERIOD	SHIPPING CONDITIONS	ANALYSIS TYPE	PROGRAMME TYPE
<b>Group B Streptococcus</b>							<b>Pg 09</b>
GBS21	QAB174200_1	1	8	Q4	Dry-ice	Qualitative	Bacterial EQA
<b>Helicobacter pylori</b>							<b>Pg 10</b>
H.PYLORI21	QAB164190_1	1	10	Q3	Dry-ice	Qualitative	Bacterial EQA
<b>Hepatitis A virus (HAV)</b>							<b>Pg 33</b>
HAVRNA21	QAV124156_1	1	8	Q3	Dry-ice	Qualitative	Viral EQA
	QAV124156_2	2	4	Q1, Q3			
<b>Hepatitis B virus (HBV)</b>							<b>Pg 34</b>
HBVDNA21	QAV994110_1	1	8	Q3	Dry-ice	Qualitative & Quantitative	Viral EQA
	QAV994110_2	2	4	Q1, Q3			
	QAV994110_4	4	4	Q1, Q2, Q3, Q4			
<b>Hepatitis B virus (HBV) Dried Blood Spots</b>							<b>Pg 52</b>
HBVDBS21	QAV214223_1	1	8	Q4	Ambient	Qualitative	Pilot Study
<b>Hepatitis B virus (HBV) Drug Resistance</b>							<b>Pg 34</b>
HBVDR21	QAV124160_1	1	5	Q3	Dry-ice	Drug Resistance / Sequencing	Viral EQA
<b>Hepatitis B virus (HBV) Genotyping</b>							<b>Pg 35</b>
HBVGT21	QAV064118_1	1	8	Q1	Dry-ice	Typing	Viral EQA
<b>Hepatitis C virus (HCV)</b>							<b>Pg 35</b>
HCVRNA21	QAV994112_1	1	8	Q3	Dry-ice	Qualitative & Quantitative	Viral EQA
	QAV994112_2	2	4	Q1, Q3			
	QAV994112_4	4	4	Q1, Q2, Q3, Q4			
<b>Hepatitis C virus (HCV) Dried Blood Spots</b>							<b>Pg 53</b>
HCVDBS21	QAV214222_1	1	8	Q4	Ambient	Qualitative	Pilot Study
<b>Hepatitis C virus (HCV) Drug Resistance</b>							<b>Pg 36</b>
HCVDR21	QAV134167_1	1	5	Q3	Dry-ice	Drug Resistance / Sequencing	Viral EQA
<b>Hepatitis C virus (HCV) Genotyping</b>							<b>Pg 36</b>
HCVGT21	QAV034117_1	1	8	Q1	Dry-ice	Typing	Viral EQA
<b>Hepatitis D virus (HDV)</b>							<b>Pg 37</b>
HDV21	QAV144170_1	1	8	Q3	Dry-ice	Qualitative & Quantitative	Viral EQA
<b>Hepatitis E virus (HEV)</b>							<b>Pg 37</b>
HEVRNA21	QAV124157_1	1	8	Q3	Dry-ice	Qualitative & Quantitative	Viral EQA
<b>Herpes simplex virus 1 &amp; 2 (HSV)</b>							<b>Pg 38</b>
HSVDNA21	QAV994105_1	1	10	Q3	Dry-ice	Qualitative	Viral EQA
	QAV994105_2	2	5	Q1, Q3			
<b>Herpes simplex virus Drug Resistance</b>							<b>Pg 38</b>
HSVDR21	QAV164184_1	1	5	Q1	Dry-ice	Sequence Analysis	Viral EQA
<b>Human Immunodeficiency virus (HIV) Dried Blood Spots</b>							<b>Pg 53</b>
HIVDBS21	QAV214221_1	1	8	Q4	Ambient	Qualitative	Pilot Study
<b>Human Immunodeficiency virus type 2 (HIV-2)</b>							<b>Pg 54</b>
HIV2_21	QAV204212_1	1	8	Q3	Dry-ice	Qualitative & Quantitative	Pilot Study
	QAV204212_2	2	4	Q1, Q3			



TARGET PATHOGEN							PAGE NUMBER
PROGRAMME CODE	CATALOGUE NUMBER	NO. OF CHALLENGES	PANEL MEMBERS PER CHALLENGE	DISTRIBUTION DATE(S)/ TESTING PERIOD	SHIPPING CONDITIONS	ANALYSIS TYPE	PROGRAMME TYPE
<b>Human herpes virus 6 (HHV6)</b>							<b>Pg 39</b>
HHV6DNA21	QAV084119_1	1	10	Q3	Dry-ice	Qualitative & Quantitative	Viral EQA
	QAV084119_2	2	5	Q2, Q3			
<b>Human Immunodeficiency virus type 1 (HIV-1) – DNA</b>							<b>Pg 39</b>
HIVDNA21	QAV034114_1	1	8	Q3	Dry-ice	Qualitative	Viral EQA
	QAV034114_2	2	4	Q1, Q3			
<b>Human Immunodeficiency virus type 1 (HIV-1) – Drug Resistance</b>							<b>Pg 40</b>
HIVDR21	QAV024131_1	1	5	Q3	Dry-ice	Drug Resistance / Sequencing	Viral EQA
<b>Human Immunodeficiency virus type 1 (HIV-1) – Drug Resistance (Integrase)</b>							<b>Pg 40</b>
HIVDRint21	QAV114146_1	1	5	Q3	Dry-ice	Drug Resistance / Sequencing	Viral EQA
<b>Human Immunodeficiency virus type 1 (HIV-1) – RNA</b>							<b>Pg 41</b>
HIVRNA21	QAV994108_1	1	8	Q3	Dry-ice	Qualitative & Quantitative	Viral EQA
	QAV994108_2	2	4	Q1, Q3			
	QAV994108_4	4	4	Q1, Q2, Q3, Q4			
<b>Human metapneumovirus (MPV)</b>							<b>Pg 41</b>
MPV21	QAV054135_1	1	8	Q2	Dry-ice	Qualitative	Viral EQA
<b>Human Papillomavirus (HPV) – PreservCyt</b>							<b>Pg 42</b>
HPVPRES21	QAV094130_1	1	12	Q4	Ambient / Specialist	Qualitative	Viral EQA
	QAV094130_2	2	6	Q2, Q4			
<b>Human Papillomavirus (Surepath)</b>							<b>Pg 42</b>
HPVSURE21	QAV184204_1	1	12	Q4	Ambient	Qualitative	Viral EQA
<b>Influenza A &amp; B virus (FLU)</b>							<b>Pg 43</b>
INFRNA21	QAV054134_1	1	10	Q4	Dry-ice	Qualitative	Viral EQA
	QAV054134_2	2	5	Q2, Q4			
<b>Influenza Haemagglutinin Typing</b>							<b>Pg 43</b>
INTP21	QAV064138_1	1	8	Q4	Dry-ice	Typing	Viral EQA
<b>JC virus (JCV)</b>							<b>Pg 44</b>
JCDNA21	QAV074106_1	1	10	Q3	Dry-ice	Qualitative & Quantitative	Viral EQA
	QAV074106_2	2	5	Q2, Q3			
<b>Legionella pneumophila</b>							<b>Pg 10</b>
LPDNA21	QAB044122_1	1	10	Q1	Dry-ice	Qualitative	Bacterial EQA
<b>Malaria</b>							<b>Pg 54</b>
MALARIA21	QAP214218_1	1	10	Q4	Ambient	Qualitative	Pilot Study
<b>MALDI-TOF</b>							<b>Pg 21</b>
MALDI21	QAB124155_1	1	10	Q3	Dry-ice	Typing	Multi-Pathogen / Syndromic EQA
<b>Measles / Mumps</b>							<b>Pg 44</b>
MM21	QAV144171_1	1	10	Q3	Dry-ice	Qualitative	Viral EQA
<b>MERS coronavirus (MERS-CoV)</b>							<b>Pg 45</b>
MERS21	QAV154181_1	1	8	Q2	Dry-ice	Qualitative	Viral EQA
<b>Methicillin Resistant Staphylococcus aureus (MRSA)</b>							<b>Pg 11</b>
MRSADNA21	QAB064124_1	1	10	Q4	Ambient	Qualitative	Bacterial EQA

TARGET PATHOGEN							PAGE NUMBER
PROGRAMME CODE	CATALOGUE NUMBER	NO. OF CHALLENGES	PANEL MEMBERS PER CHALLENGE	DISTRIBUTION DATE(S)/ TESTING PERIOD	SHIPPING CONDITIONS	ANALYSIS TYPE	PROGRAMME TYPE
<b>Methicillin Resistant <i>Staphylococcus aureus</i> (MRSA) – Typing</b>							<b>Pg 11</b>
MRSATP21	QAB074128_1	1	8	Q4	Ambient	Typing	Bacterial EQA
<b><i>Mycobacterium tuberculosis</i> (MTB)</b>							<b>Pg 12</b>
MTBDNA21	QAB014129_1 QAB014129_2	1 2	10 5	Q4 Q2, Q4	Ambient	Qualitative	Bacterial EQA
<b><i>Mycobacterium tuberculosis</i> Drug Resistance</b>							<b>Pg 12</b>
MTBDR21	QAB194209_1	1	8	Q4	Ambient	Typing	Bacterial EQA
<b><i>Mycoplasma genitalium</i></b>							<b>Pg 13</b>
MG21	QAB184205_1	1	10	Q3	Dry-ice	Qualitative	Bacterial EQA
<b><i>Mycoplasma pneumoniae</i></b>							<b>Pg 13</b>
MP21	QAB174192_1	1	5	Q2	Dry-ice	Qualitative	Bacterial EQA
<b><i>Mycoplasma</i> spp. (cell contamination)</b>							<b>Pg 14</b>
MYCO21	QAB144168_1	1	10	Q4	Dry-ice	Qualitative & Quantitative	Bacterial EQA
<b><i>Neisseria gonorrhoeae</i></b>							<b>Pg 14</b>
NgDNA21	QAB034126_1 QAB034126_2	1 2	10 5	Q3 Q1, Q3	Dry-ice	Qualitative	Bacterial EQA
<b>Norovirus (NV)</b>							<b>Pg 45</b>
NVRNA21	QAV084139_1 QAV084139_2	1 2	10 5	Q4 Q2, Q4	Dry-ice	Qualitative	Viral EQA
<b>Parainfluenza virus (PIV)</b>							<b>Pg 46</b>
PINFRNA21	QAV064136_1	1	10	Q2	Dry-ice	Qualitative	Viral EQA
<b>Parasitic Gastroenteritis</b>							<b>Pg 22</b>
GastroP21	QAP124154_1 QAP124154_2	1 2	10 5	Q4 Q2 & Q4	Dry-ice	Qualitative	Multi-Pathogen / Syndromic EQA
<b>Parechovirus (HPeV)</b>							<b>Pg 46</b>
PeVRNA21	QAV114145_1 QAV114145_2	1 2	10 5	Q3 Q1, Q3	Dry-ice	Qualitative	Viral EQA
<b><i>Pneumocystis jirovecii</i> pneumonia (PCP)</b>							<b>Pg 18</b>
PCPDNA21	QAF114144_1	1	10	Q3	Dry-ice	Qualitative & Quantitative	Fungal EQA
<b>Respiratory I</b>							<b>Pg 22</b>
RESPI21	QAV164188_1 QAV164188_2	1 2	10 5	Q3 Q1, Q3	Dry-ice	Qualitative	Multi-Pathogen / Syndromic EQA
<b>Respiratory I Plus</b>							<b>Pg 55</b>
RESPIplus21	QAM204216_1	1	10	Q3	Dry-ice	Qualitative	Pilot Study
<b>Respiratory II</b>							<b>Pg 23</b>
RESPII21	QAV164189_1 QAV164189_2	1 2	10 5	Q3 Q1, Q3	Dry-ice	Qualitative	Multi-Pathogen / Syndromic EQA
<b>Respiratory III</b>							<b>Pg 23</b>
RESPIII21	QAM174193_1 QAM174193_2	1 2	10 5	Q3 Q1, Q3	Dry-ice	Qualitative	Multi-Pathogen / Syndromic EQA
<b>Respiratory syncytial virus (RSV)</b>							<b>Pg 47</b>
RSV21	QAV054142_1 QAV054142_2	1 2	10 5	Q4 Q2, Q4	Dry-ice	Qualitative	Viral EQA
<b>Rhinovirus (RV)</b>							<b>Pg 47</b>
RVRNA21	QAV064143_1	1	10	Q2	Dry-ice	Qualitative	Viral EQA

TARGET PATHOGEN							PAGE NUMBER
PROGRAMME CODE	CATALOGUE NUMBER	NO. OF CHALLENGES	PANEL MEMBERS PER CHALLENGE	DISTRIBUTION DATE(S)/ TESTING PERIOD	SHIPPING CONDITIONS	ANALYSIS TYPE	PROGRAMME TYPE
<b>SARS-CoV-2</b>							<b>Pg 48</b>
SCV2_21	QAV204215_1A	1	5	Q1	Dry-ice	Qualitative	Viral EQA
	QAV204215_1B	1	5	Q2			
	QAV204215_1C	1	5	Q3			
	QAV204215_1D	1	5	Q4			
<b>Sepsis</b>							<b>Pg 24</b>
SEPSIS21	QAB164178_1	1	10	Q4	Dry-ice	Qualitative	Multi-Pathogen / Syndromic EQA
<b>Sexually Transmitted Infections I</b>							<b>Pg 24</b>
STL_I21	QAB154177_1	1	10	Q3	Dry-ice	Qualitative	Multi-Pathogen / Syndromic EQA
	QAB154177_2	2	5	Q2, Q3			
<b>Sexually Transmitted Infections II</b>							<b>Pg 25</b>
STL_II21	QAM174201_1	1	10	Q3	Dry-ice	Qualitative	Multi-Pathogen / Syndromic EQA
	QAM174201_2	2	5	Q2, Q3			
<b>Staphylococcus aureus spa</b>							<b>Pg 15</b>
SASPA21	QAB134164_1	1	6	Q4	Ambient	Typing	Bacterial EQA
<b>Syphilis</b>							<b>Pg 15</b>
SYPH21	QAB154180_1	1	8	Q4	Dry-ice	Qualitative	Bacterial EQA
<b>Torque teno virus (TTV)</b>							<b>Pg 48</b>
TTV21	QAV184203_1	1	6	Q4	Dry-ice	Qualitative	Viral EQA
<b>Toxoplasma gondii</b>							<b>Pg 18</b>
TGDNA21	QAP044123_1	1	10	Q4	Ambient	Qualitative	Fungal EQA
	QAP044123_2	2	5	Q2, Q4			
<b>Transplantation (viral)</b>							<b>Pg 25</b>
TRANS21	QAM174198_1	1	10	Q3	Dry-ice	Qualitative & Quantitative	Multi-Pathogen / Syndromic EQA
	QAM174198_2	2	5	Q2, Q4			
<b>Trichomonas vaginalis</b>							<b>Pg 18</b>
TV21	QAP184202_1	1	8	Q3	Dry-ice	Qualitative	Fungal EQA
<b>Vancomycin Resistant Enterococci (VRE)</b>							<b>Pg 16</b>
VRE21	QAB134163_1	1	10	Q3	Dry-ice	Qualitative	Bacterial EQA
<b>Varicella-Zoster virus (VZV)</b>							<b>Pg 49</b>
VZVDNA21	QAV034103_1	1	10	Q3	Dry-ice	Qualitative	Viral EQA
	QAV034103_2	2	5	Q1, Q3			
<b>Viral Gastroenteritis</b>							<b>Pg 25</b>
GastroV21	QAV124152_1	1	10	Q4	Dry-ice	Qualitative	Multi-Pathogen / Syndromic EQA
	QAV124152_2	2	5	Q2, Q4			
<b>Viral Metagenomics NGS</b>							<b>Pg 55</b>
NGSmta_21	QAV204213_1	1	5	Q4	Dry-ice	Qualitative	Pilot Study
<b>West Nile virus (WNV)</b>							<b>Pg 49</b>
WNVRNA21	QAV104141_1	1	10	Q4	Ambient	Qualitative	Viral EQA
<b>Yellow fever virus</b>							<b>Pg 50</b>
YFV21	QAM194207_1	1	8	Q4	Ambient	Qualitative	Viral EQA
<b>Zika virus</b>							<b>Pg 50</b>
ZIKA21	QAV164186_1	1	10	Q4	Ambient	Qualitative	Viral EQA

[www.qcmd.org](http://www.qcmd.org)  
**RANDOX**

Randox are authorised by QCMD to provide the QCMD EQA schemes under a strategic global partnership. The EQA design, composition, data analysis & reporting remain the responsibility of QCMD. Please refer to specific geographical regions for further details on availability.



LT739 NOV20